Global Allogeneic T Cell Therapies Market Strategies 2024, Forecast To 2033
12 Nov, 2024
The allogeneic T cell therapies market has witnessed substantial growth, expected to rise from $1.06 billion in 2023 to $1.16 billion in 2024 with a CAGR of 9.8%. This growth has been driven by regulatory approvals, rising cancer prevalence, increased clinical trials, government funding, and a growing elderly population. The allogeneic T cell therapies market is forecast to grow to $1.69 billion by 2028, with a CAGR of 9.9%. The expansion is driven by expanding therapeutic indications, growing demand for cell-based immunotherapies, rising healthcare expenditure, and supportive reimbursement policies. Trends include advancements in research, personalized medicine, off-the-shelf therapies, market expansion, strategic partnerships, and regulatory changes.
Major Driver In The Allogeneic T Cell Therapies Market
The growing automotive industry is expected to propel the alkyd resin market in the coming years. The automotive sector is expanding due to the increasing demand for electric vehicles (EVs), supported by government incentives. Alkyd resins are essential in automotive applications due to their durability and high-gloss finish, providing vehicles with long-lasting protection and an appealing surface. In July 2023, global motor vehicle production reached 85.4 million units, marking a 5.7% rise from the previous year. The growth of the automotive industry is expected to drive the alkyd resin market, with projections of $1.3 billion by 2024 and $1.7 billion by 2028.
Request A Free Sample Of The Allogeneic T Cell Therapies Market ReportAllogeneic T Cell Therapies Market Competitive Landscape
Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Immatics NV, Sangamo Therapeutics Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Sorrento Therapeutics Inc., Autolus Therapeutics Plc, MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Enlivex Therapeutics Ltd., Cellectis SA, Adaptimmune Therapeutics Plc, Medigene AG, Celyad Oncology SA, Allogene Therapeutics Inc., Bellicum Pharmaceuticals Inc.
Key Allogeneic T Cell Therapies Market Trend
Companies in the allogeneic T-cell therapies market are advancing chimeric antigen receptor (CAR) T-cell therapies to improve cancer treatments. In October 2022, Allogene Therapeutics Inc. launched CAR T Together, an initiative to simplify clinical trial enrollment and accelerate the development of allogeneic CAR T therapies, which use T cells from healthy donors for more efficient manufacturing.
Purchase The Global Allogeneic T Cell Therapies Market Report Directly And Get A Swift DeliveryGlobal Allogeneic T Cell Therapies Market Segmentation
The allogeneic T cell therapies market covered in this report is segmented –
1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies, Other Product Types
2) By Antigen Type: CD 19, CD 20, Egfrvlll, GD2, CD22, CD30, CD33, Meso, HER1, Other Antigen Types
3) By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Others Therapeutics Indications
4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
By Geography:The regions covered in the allogeneic T cell therapies market report areAustralia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the allogeneic T cell therapies market in 2023.
The Allogeneic T Cell Therapies Global Market Report 2024 furnishes information about the global allogeneic t cell therapies market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.